Zentalis Pharmaceuticals Inc. (ZNTL) News
Filter ZNTL News Items
ZNTL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ZNTL News Highlights
- ZNTL's 30 day story count now stands at 2.
- Over the past 26 days, the trend for ZNTL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC are the most mentioned tickers in articles about ZNTL.
Latest ZNTL News From Around the Web
Below are the latest news stories about ZENTALIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZNTL as an investment opportunity.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK and SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on December 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 42,000 shares of the Company’s common stock and 28,0 |
David Johnson Bought 16% More Shares In Zentalis PharmaceuticalsInvestors who take an interest in Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) should definitely note that the... |
Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc SharesIn the realm of stock market movements, insider trading activity is often a significant indicator that investors monitor to gauge the confidence of management and key stakeholders in the company's future. |
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD CowenInvestor call to be held on Friday, November 10th, at 10:00 a.m. ET Company also to participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15th, 2023 at 8:30 a.m. GMT NEW YORK and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, toda |
Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational UpdatesCompany on track for first NDA submission in a gynecologic malignancy in 2026 with a cash balance of $517 million |
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational UpdatesUpdated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on track for first NDA submission in a gynecologic malignancy in 2026 Sharing key clinical milestones through 2026 for azenosertib and ZN-d5 $517 million cash balance as of September 30, 2023, with projected cash runway into 2026 Chief Translational Officer, Mark Lackner, Ph.D., to succeed Co-Founder, K |
Insider Sell: Chief Medical Officer Carrie Brownstein Sells 10,628 Shares of Zentalis ...On October 4, 2023, Carrie Brownstein, the Chief Medical Officer of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL), sold 10,628 shares of the company. |
Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL)On September 11, 2023, Director Jan Skvarka sold 5,000 shares of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL). |
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceNEW YORK and SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 |